Compare IFN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFN | IMMX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.6M | 629.3M |
| IPO Year | 1994 | 2021 |
| Metric | IFN | IMMX |
|---|---|---|
| Price | $11.60 | $9.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.20 |
| AVG Volume (30 Days) | 175.3K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $1.94 |
| 52 Week High | $16.60 | $11.61 |
| Indicator | IFN | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 58.15 |
| Support Level | $10.84 | $7.99 |
| Resistance Level | $11.79 | $10.61 |
| Average True Range (ATR) | 0.17 | 0.65 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 96.74 | 87.11 |
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.